Malignant Pleural effusion. Secondary malignant neoplasm of pleura
Conditions
Interventions
After inserting a pleural catheter and dranage of Pleural fluid, Cisplatin with 30 Mg/ dl was injected via cathater. In two weeks time points for three sassion..
Treatment - Drugs
After inserting a pleural catheter and dranage of Pleural fluid, Cisplatin with 30 Mg/ dl was injected via cathater. In two weeks time points for three sassion.
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria: Patients diagnosed with malignant pleural effusion who admitted from August 2016 till February 2017 in Masih Daneshvari hospital. Patients with Lung Carcinoma, Breast cancer and Mesothelium who their pleural effusion diagnosed and confirmed by Cytology results of pleurla fluid. Patients who received Pleurodesis treatment with Sclerosant material.However, still shows symptom. Also patients who had Malignant pleural effusion but haven't response to systemic Chemptherapy or were not candidate to treat by systematic chemotherapy. Also, patients who the clinical and radiological symptoms were stable after one week treatment. Exclusion Criteria: The patient's unwillingness to continue to cooperate, cancers other than lung, breast or mesothelioma, a condition prohibiting the use of cisplatin and kidney and bloodconditions in the patient.
Exclusion criteria
Exclusion criteria:
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Electrolyte Disorder. Timepoint: Each two weeks. Method of measurement: Decrease in Calcium.;Electrolyte disorder. Timepoint: Each two weeks. Method of measurement: Decrease in Magnesium, lower than 1.8 mg/dl.;Electrolyte disorders. Timepoint: Each two weeks. Method of measurement: Decrease of Potassium lower than 5.3 meq/dl.;Bone marrow suppression. Timepoint: Each two weeks. Method of measurement: The bone marrow suppression with drop in WBC to the lower 4000/l or Neutrophils lower than 1500/l or Platelets lower than 100000 or drop in one unit of HB in comparision with post treatment condition.;Shortness of breath. Timepoint: after two weeks. Method of measurement: Borg scale.;Estimation of Pleural effusion. Timepoint: 1 month after injection. Method of measurement: Based onamonth of Pleural fluid. | — |
Primary
| Measure | Time frame |
|---|---|
| WBC. Timepoint: Before each injection, each 2 weeks. Method of measurement: Blood test.;Plt. Timepoint: Before each injection, each 2 weeks. Method of measurement: Blood test.;Hb. Timepoint: Before each injection, each 2 weeks. Method of measurement: Blood test.;Cr. Timepoint: Before each injection, each 2 weeks. Method of measurement: Blood test.;Na. Timepoint: Before each injection, each 2 weeks. Method of measurement: Blood test.;K. Timepoint: Before each injection, each 2 weeks. Method of measurement: Blood test.;Ca. Timepoint: Before each injection, each 2 weeks. Method of measurement: Blood test.;Mg. Timepoint: Before each injection, each 2 weeks. Method of measurement: Blood test.;Estimation of pleural fluid. Timepoint: Before each injection, each 2 weeks. Method of measurement: Chest X ray. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAtefeh Abedini
Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung D
Outcome results
None listed